[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-337354-105":3,"doc-detail-337354-en":81,"detail-sidebar-cat-0-en-105":116},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","er-positive-and-brca2-mutated-breast-cancer-a-literature-review","ER-positive and BRCA2-mutated breast cancer: a literature review","","BRCA2-mutated carriers face a high lifetime breast cancer risk, with early onset and elevated risk of other malignancies such as ovarian, pancreatic, and prostate cancer. Around 70–80% of BRCA2-mutated breast cancers are estrogen receptor (ER)-positive, forming a distinct subgroup from sporadic ER-positive disease. This review summarizes clinicopathological characteristics, treatment approaches, and prognosis to support evidence-based clinical decision-making, while discussing underlying interactions and therapeutic implications.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/er-positive-and-brca2-mutated-breast-cancer-a-literature-review/337354/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/er-positive-and-brca2-mutated-breast-cancer-a-literature-review/337354.png","ImageObject",300,407,{"name":42,"@type":43},"Jiven","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is ER-positive BRCA2-mutated breast cancer considered distinct from sporadic ER-positive breast cancer?","Question",{"text":63,"@type":64},"About 70–80% of BRCA2-mutated breast cancers are ER-positive, but this subgroup differs from sporadic ER-positive disease. The review highlights distinct clinical features and outcomes to reflect these differences.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What are the main treatment modalities discussed for ER-positive metastatic breast cancer?",{"text":68,"@type":64},"Endocrine therapy is described as the primary treatment, with CDK4/6 inhibitors used as first-line therapy for ER-positive metastatic disease. Abemaciclib plus endocrine therapy is also noted for improving invasive disease-free survival in high-recurrence-risk patients.",{"name":70,"@type":61,"acceptedAnswer":71},"How do PARP inhibitors relate to BRCA2 mutations?",{"text":72,"@type":64},"BRCA2 mutations cause homologous recombination repair defects, which may increase susceptibility to DNA damage–inducing drugs. The review specifically discusses PARP inhibitors (including in combination with immune checkpoint inhibitors) as promising options.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},337354,1790660903,{"code":4,"msg":82,"data":83},"success",{"doc_id":79,"user_id":84,"nickname":42,"user_avatar":85,"doc_module":4,"category_id":86,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":87,"file_id":88,"file_url":89,"file_type":90,"file_size":91,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":92,"language":93,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":94,"faqs":95,"seo_title":96,"seo_description":12,"update_tm":97,"read_time":98,"preview_page_count":33,"preview_urls":99},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399",8,"Li etal. European Journal of Medical Research (2024) 29:30  \n[https://doi.org/10.1186/s40001-023-01618-1](https://doi.org/10.1186/s40001-023-01618-1)  \nEuropean Journal of Medical Research  \n REVIEW Open Access  \nER-positive and BRCA2-mutated breast cancer: a literature review  \nPu‑Chun Li 1,2†, Yi‑Fan Zhu 1,2†, Wen‑Ming Cao2* and Bei Li3*  \nAbstract  \nBRCA2‑mutated carriers have a high lifetime risk of breast cancer (BC), an early age of onset, and an increased risk of other cancers (including ovarian, pancreatic, and prostate cancer) . Almost 70–80% of BRCA2‑mutated BC are estrogen receptor (ER)‑positive, which is a particular type of ER‑positive BC that differs from sporadic ER‑positive BC. This article reviews the clinicopathological features, treatment, and prognosis of ER‑positive and BRCA2‑mutated BC to provide a reference for clinical decision‑making.  \nKeywords Breast cancer, BRCA2 mutation, ER‑positive, PARP inhibitor, CDK4/6 inhibitor, Survival rate  \nIntroduction  \nThe most prevalent malignancy and the main reason for cancer-related mortality in women globally is BC [1]. It has been established that the development of BC is mainly the result of a multifactorial interaction of genetic, environmental, and lifestyle factors. BRCA2 is one of the most prevalent BC susceptibility gene. The lifetime risk of developing BC in germline BRCA2-mutated carriers is approximately 55%, significantly higher than non-carriers [2]. However, the difference in prognosis between BRCA2-mutated and non-mutated BC is still controversial [3]. One study found that the majority of females with a BRCA2 mutation have ER-positive and human epidermal receptor 2 (HER2)-negative BC [4]. Among sporadic BC, ER-positive BC are often characterized by late age  \n†Pu‑Chun Li andYi‑Fan Zhu have contributed equally to this work.  \n*Correspondence: Wen‑Ming Cao [caowm@zjcc.org.cn](caowm@zjcc.org.cn)[ ](caowm@zjcc.org.cn)Bei Li[libeibei9702@126.com](libeibei9702@126.com)  \n1 Postgraduate Training Base Alliance of Wenzhou Medical University (Zhejiang Cancer Hospital), Hangzhou 310022, China  \n2 Department of Breast Medical Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, China  \n3 Department of Geriatric, Affiliated Hangzhou First People’s Hospital, School of Medicine, Westlake University, Hangzhou 310006, China  \nof onset, low pathological grade, and low rate of lymph node metastasis and have a significantly better prognosis than do ER-negative BC [5, 6]. However, studies have shown that the risk of death is higher in ER-positive than in ER-negative BC with a BRCA2 mutation and that ER positivity is an independent prognostic factor [7].  \nEndocrine therapy is the primary treatment modality for ER-positive BC, and in combination with cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors is currently the first-line therapy for ER-positive metastatic BC [8–10]. Moreover, abemaciclib combined with endocrine therapy enhanced invasive disease-free survival (iDFS) in ER-positive patients with high risk of recurrence [11]. However, it has been found that germline BRCA2-mutated BC are often associated with copy number loss of the Rb1 gene, leading to CDK4/6 inhibitors resistance [12]. Therefore, the optimal therapy strategy for ER-positive, BRCA2-mutated BC is currently unclear. In addition, the BRCA2 mutation causes homologous recombination repair defects and may be more susceptible to DNA damage drugs such as poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors and platinum. PARP inhibitors combined with immune checkpoint inhibitors (ICIs) have also demonstrated favorable performance in the management of ER-positive and BRCA2-mutated BC [13]. The regulatory relationship between ER and BRCA2 should be investigated to  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you giv","cbCaifHnxDMqzwXr","https://ap.wps.com/l/cbCaifHnxDMqzwXr","pdf",1299952,11,"English","# Introduction\n## Epidemiology and risk\n## Treatment background and current challenges\n# Interaction between ER signaling pathway and BRCA2\n## BRCA2 functions and DNA damage repair\n## Clinical phenotype implications\n# Endocrine therapy and targeted treatments\n## CDK4/6 inhibitors and resistance context\n## PARP inhibitors and platinum susceptibility\n# Review scope and clinical relevance","[{\"question\":\"Why is ER-positive BRCA2-mutated breast cancer considered distinct from sporadic ER-positive breast cancer?\",\"answer\":\"About 70–80% of BRCA2-mutated breast cancers are ER-positive, but this subgroup differs from sporadic ER-positive disease. The review highlights distinct clinical features and outcomes to reflect these differences.\"},{\"question\":\"What are the main treatment modalities discussed for ER-positive metastatic breast cancer?\",\"answer\":\"Endocrine therapy is described as the primary treatment, with CDK4/6 inhibitors used as first-line therapy for ER-positive metastatic disease. Abemaciclib plus endocrine therapy is also noted for improving invasive disease-free survival in high-recurrence-risk patients.\"},{\"question\":\"How do PARP inhibitors relate to BRCA2 mutations?\",\"answer\":\"BRCA2 mutations cause homologous recombination repair defects, which may increase susceptibility to DNA damage–inducing drugs. The review specifically discusses PARP inhibitors (including in combination with immune checkpoint inhibitors) as promising options.\"}]","ER-positive and BRCA2-mutated breast cancer: a literature review | PDF",1790018743,28,[100,104,108,112],{"page_no":22,"url":101,"width":102,"height":103},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b46ff1891d9f73d2a84b23060e4dbf02.webp",983,1305,{"page_no":26,"url":105,"width":106,"height":107},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f4b834c7156fde8202288c7a8376db77.webp",982,1304,{"page_no":30,"url":109,"width":110,"height":111},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d472377225abd152eef5447f669d804a.webp",981,1303,{"page_no":33,"url":113,"width":114,"height":115},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/002c754bd63d8d2989a97e874cd5a0c1.webp",980,1301,{"code":4,"msg":82,"data":117},[118,122,126,130,135,140,145,148,153,156,159],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":119,"show_sort_weight":120,"slug":121},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":123,"show_sort_weight":124,"slug":125},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":127,"show_sort_weight":128,"slug":129},"Exam",70,"exam",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":133,"slug":134},5,"Comic",60,"comic",{"id":136,"doc_module":4,"doc_module_name":25,"category_name":137,"show_sort_weight":138,"slug":139},6,"Technology",50,"technology",{"id":141,"doc_module":4,"doc_module_name":25,"category_name":142,"show_sort_weight":143,"slug":144},7,"Healthcare",40,"healthcare",{"id":86,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":146,"slug":147},30,"research-report",{"id":149,"doc_module":4,"doc_module_name":25,"category_name":150,"show_sort_weight":151,"slug":152},9,"Religion & Spirituality",20,"religion-spirituality",{"id":151,"doc_module":4,"doc_module_name":25,"category_name":154,"show_sort_weight":151,"slug":155},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":157,"show_sort_weight":55,"slug":158},"Lifestyle","lifestyle",{"id":160,"doc_module":4,"doc_module_name":25,"category_name":161,"show_sort_weight":131,"slug":162},19,"General","general"]